Environmental

Voyager Therapeutics’ R&D intensity supports a lower direct environmental footprint than manufacturing-heavy peers, but the metric mainly reflects business model rather than disclosed environmental controls.

The company’s capital-light structure likely reduces energy, water, and waste exposure versus industrial peers, yet the absence of disclosed operational ESG metrics limits relative confidence.

No material environmental controversies or emissions disclosures were provided, so the environmental profile appears neutral rather than advantaged versus biotech peers.

Compared with larger life-science peers that publish more detailed climate and resource data, Voyager appears less transparent, which weakens its relative environmental positioning.

Social

High R&D spending relative to revenue indicates a science-driven model that can support patient-focused innovation, but it does not by itself demonstrate stronger social outcomes than peers.

Stock-based compensation at 34.5% of revenue suggests meaningful employee alignment, although it can also signal dilution pressure relative to better-capitalized biotech peers.

No workforce, safety, clinical-trial, or access-to-medicine disclosures were provided, so the social assessment remains constrained versus peers with fuller reporting.

As a development-stage biotech, Voyager’s social risk is concentrated in trial execution and patient safety, which is broadly similar to peers rather than clearly better.

Governance

Debt-to-equity of 0.21 and net debt to EBITDA near zero indicate limited balance-sheet leverage, which reduces creditor pressure and supports governance flexibility versus more indebted peers.

The very high stock-based compensation burden relative to revenue can dilute shareholders and may indicate weaker capital discipline than peers with tighter compensation controls.

Negative gross profit margin reflects an early-stage operating model, but governance relevance is mainly through capital allocation oversight rather than operating performance itself.

Without filing-based board, audit, or ownership detail, Voyager’s governance profile appears average relative to biotech peers rather than structurally superior.

Overall Score

Voyager Therapeutics appears broadly average versus biotech peers, with modest strengths in capital-light structure and leverage, offset by limited ESG disclosure depth.

Score Driver: Limited Disclosure And Only Modest Peer-Relative Advantages Across The Most Material ESG Dimensions.